Granulocyte and monocyte/macrophage apheresis for the treatment of immune-mediated inflammatory arthropathies: case reports

Ana Victoria Carro Martínez, Lydia Montolio Chiva, Montserrat Robustillo Villarino

Abstract

Drug therapy of immune-mediated inflammatory arthropathies is not always satisfactory, and there is a risk of adverse events. Granulocyte and monocyte/macrophage apheresis (GMA) is a non-pharmacological therapeutic option that is beneficial and very well tolerated. GMA involves passing blood through a column with cellulose acetate beads to remove increased and activated myeloid lineage cells and improve the cytokine profile. The technique reduces pain and inflammation. We present four clinical reports that illustrate the clinical uses of GMA with the medical device Adacolumn® in patients with different backgrounds and immune-mediated inflammatory arthritis. The results were positive, and no adverse events were reported.

Article Details

Article Type

Case Report

DOI

10.7573/dic.2021-8-5

Categories

Publication Dates

Accepted: ; Published: .

Citation

Carro Martínez AV, Montolio Chiva L, Robustillo Villarino M. Granulocyte and monocyte/macrophage apheresis for the treatment of immune-mediated inflammatory arthropathies: case reports. Drugs Context. 2021;10:2021-8-5. https://doi.org/10.7573/dic.2021-8-5

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.